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Purpose
Scleritis is a chronic vasculitis of scleral vessels leading to a
substantial amount of morbidity and even blindness. Oral
steroids and intensive immunosuppressive treatments are
often used to to achieve long-term control of disease. But
those drugs have severe adverse effects and there is a sig-
nificant number of non-responders. We describe six
patients with refractory scleritis who received rituximab.
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A case series of six patients (aged 39-66) with refractory
scleritis (4 idiopathic, 2 relapsing polychondritis), includ-
ing B cell monitoring. One treatment cycle consisted of
1000 mg initially and 1000 mg two week later. Prior to
infusion 100 mg methyprednisolon was administered i.v.
Results
In all patients disease activity decreased. However, in
four patients symptoms returned resp. 2,4,6 and 9
months after therapy. In two cases complete remission
was achieved. Two patients received a second rituximab
cycle successfully. No correlation was found between B
cells reoccurrence and refractory disease. [Figure 1]
Conclusions
Clinical activity of scleritis in all patients decreased after
treatment. In two cases scleritis went in complete remis-
sion after one cycle of treatment. Rituximab may be a
new promising therapeutic tool in the treatment of
refractory scleritis. There is no correlation between
relapses and B cell recovery.
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